The Asia Society Policy Institute (ASPI) and the Memorial Sloan Kettering Cancer Center (MSK) have been working together since 2017 to enhance collaboration between the U.S., China, and the rest of the world in tackling the common enemy of cancer. This collaborative effort aims to accelerate the eradication of cancer as a major cause of death (or a cure for cancer) in a lifetime, through multi-stakeholder, multi-regional collaboration on patient-centric clinical trials and international regulatory harmonization.
Continuing the collaboration between ASPI and MSK, the Bloomberg New Economy International Cancer Coalition (the “Coalition”) was launched in 2021 at the Bloomberg New Economy Forum in Singapore. The Coalition brings together public-private sector leading representatives from academia, government regulatory agencies, the pharmaceutical and biotechnology industry, and patient advocacy groups across North America, Europe, and Asia. These global representatives advocate for strengthening international clinical trial collaboration in order to accelerate the development, access, and approval of cancer treatments and prevention that could save millions of lives. In the process, it also demonstrates the potential lifesaving results that can be the outcome of cooperation between experts in the United States, China, Europe, and beyond.
Together with our staff, fellows, strategic partners, and institutional collaborators, including Bloomberg New Economy, Forbes China, the Chinese Thoracic Oncology Group (CTONG), and the Thoracic Oncology Group Australasia (TOGA), we are launching a public education initiative to raise global awareness of this important work and to empower patients and their families, physicians and the general public with the knowledge that will support cancer screening and clinical trial enrollment worldwide. These measures can significantly hasten the global goal of curing cancer. Our work seeks to raise public awareness of the undervalued potential of such international clinical trials, and in turn, empower policy innovations that can save more lives around the world.
“To accelerate the eradication of cancer globally, we need multi-stakeholder, multi-regional collaboration — that brings together academia, industry, government, patient advocacy and policy think tanks from different regions for collective actions — to promote both patient-centric clinical trials and international regulatory harmonization. This would not only provide global public goods by building the policy, scientific and technological infrastructure for international public health collaboration but could also become the new ping-pong diplomacy between U.S. and China, bringing some stabilizing and positive force for the bilateral relationship and beyond.”
-The Hon. Dr. Kevin Rudd, Asia Society President and CEO and Asia Society Policy Institute (ASPI) President.
“The goal is to bring the trial to the patient, maintaining established clinician-patient relationships of trust. Promoting the concept of patient-centric care, this collaborative model would ensure that trials are being offered to patients regardless of where they live. We must do better by improving patients’ access to potentially lifesaving clinical trials.”
- Dr. Bob Li, Medical Oncologist and Physician Ambassador to China and Asia-Pacific, Memorial Sloan Kettering Cancer Center; Senior Fellow on Global Public Health, Center for China Analysis at the Asia Society Policy Institute.
“Cancer is a common, transnational enemy of humanity, but it can be fixed. Better international coordination and harmonization of cancer clinical trials could save as many as two million lives every single year. A core part of our international Cure4Cancer movement is to raise public awareness of the extremely undervalued potential of international clinical trials and in turn to open up more political space, empower more policy innovations and promote patient-centric treatments globally. Hopefully in the end we can improve the lives of the millions of patients and families suffering from cancer, and accelerate the cure for cancer for the whole of humanity.”
- Jing Qian, Co-Founder and Managing Director of the Asia Society Policy Institute’s Center for China Analysis
The Cure4Cancer International Clinical Trials Collaboration (C4C) public awareness initiative at Asia Society is supported by an unrestricted education grant from AstraZeneca.